Zenotech Laboratories Ltd
Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]
- Market Cap ₹ 283 Cr.
- Current Price ₹ 46.4
- High / Low ₹ 73.5 / 44.8
- Stock P/E
- Book Value ₹ 15.8
- Dividend Yield 0.00 %
- ROCE -9.08 %
- ROE -12.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 2.96 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -14.8% over last 3 years.
- Debtor days have increased from 72.3 to 96.1 days.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
|---|---|---|---|---|---|
| 12 | 13 | 8 | 6 | 7 | |
| 15 | 19 | 18 | 24 | 16 | |
| Operating Profit | -3 | -6 | -10 | -18 | -9 |
| OPM % | -20% | -49% | -121% | -292% | -143% |
| 0 | 9 | 2 | 5 | 2 | |
| Interest | 1 | 2 | 3 | 1 | 2 |
| Depreciation | 0 | 2 | 3 | 3 | 3 |
| Profit before tax | -3 | -1 | -14 | -18 | -13 |
| Tax % | 6% | -250% | 17% | 0% | -0% |
| -4 | 2 | -16 | -18 | -13 | |
| EPS in Rs | 0.32 | -2.64 | -2.88 | -2.05 | |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -20% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 8% |
| 3 Years: | -10% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -15% |
| Last Year: | -12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
|---|---|---|---|---|---|
| Equity Capital | 16 | 29 | 34 | 34 | 34 |
| Reserves | 6 | 25 | 92 | 74 | 62 |
| 31 | 36 | 19 | 17 | 10 | |
| 21 | 10 | 8 | 5 | 4 | |
| Total Liabilities | 74 | 100 | 153 | 131 | 111 |
| 16 | 60 | 61 | 62 | 71 | |
| CWIP | 40 | 9 | 15 | 24 | 13 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 19 | 30 | 77 | 45 | 27 | |
| Total Assets | 74 | 100 | 153 | 131 | 111 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
|---|---|---|---|---|---|
| -16 | -7 | -3 | -16 | -10 | |
| -56 | -15 | -67 | 20 | 29 | |
| 74 | 22 | 70 | -4 | -8 | |
| Net Cash Flow | 2 | -0 | -0 | 1 | 11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
|---|---|---|---|---|---|
| Debtor Days | 145 | 273 | 85 | 36 | 96 |
| Inventory Days | 139 | 331 | 575 | 172 | 279 |
| Days Payable | 451 | 455 | 421 | 226 | 253 |
| Cash Conversion Cycle | -167 | 149 | 240 | -18 | 123 |
| Working Capital Days | 55 | 279 | 196 | 250 | 286 |
| ROCE % | 2% | -9% | -12% | -9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Nov - Copies of extracts of Standalone Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025 as published in newspapers …
-
Board Meeting Outcome for Approval Of Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30, 2025.
31 Oct - Board approved unaudited results for quarter/H1 ended Sep 30, 2025; H1 profit Rs15.30L, Q2 loss Rs83.65L, tax adjustment Rs190.49L.
-
Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30, 2025
31 Oct - Board approved unaudited Q2/H1 results to Sept 30, 2025; tax adjustment Rs190.49 lakh.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone Financial Results For The Quarter And Half Year Ended September 30, 2025
22 Oct - Board meeting on Oct 31, 2025 to approve Q2/H1 unaudited results for Sept 30, 2025; trading window Oct 1–Nov 2.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Oct - Certificate under Regulation 74(5) for quarter ended Sept 30, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty
generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products